Catarina Edfjäll
Net worth: - $ as of 30/05/2024
Profile
Catarina Edfjäll formerly worked at The Cancer Drug Development Forum, as Director from 2008 to 2012, International Collaboration On Rare Diseases & Orphan Drugs, as Director from 2014 to 2021, ObsEva SA, as Independent Director from 2021 to 2024, and CSL Behring AG, as Global Head-Regulatory Affairs from 2013 to 2019.
Dr. Edfjäll received her doctorate degree from the University of Basel and graduate degree from the University of Strasbourg.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
OBSEVA SA
-.--% | 23/03/2023 | 0 ( -.--% ) | - $ | 30/05/2024 |
Former positions of Catarina Edfjäll
| Companies | Position | End |
|---|---|---|
| OBSEVA SA | Director/Board Member | 17/03/2024 |
| International Collaboration On Rare Diseases & Orphan Drugs | Director/Board Member | 31/12/2020 |
CSL Behring AG
 CSL Behring AG BiotechnologyHealth Technology Part of CSL Ltd., CSL Behring AG is a Swiss company that develops biological products. The company is based in Bern, Switzerland. | General Counsel | 31/12/2018 |
| The Cancer Drug Development Forum | Director/Board Member | 31/12/2011 |
Training of Catarina Edfjäll
| University of Basel | Doctorate Degree |
| University of Strasbourg | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| OBSEVA SA | Health Technology |
| Private companies | 3 |
|---|---|
CSL Behring AG
CSL Behring AG BiotechnologyHealth Technology Part of CSL Ltd., CSL Behring AG is a Swiss company that develops biological products. The company is based in Bern, Switzerland. | Health Technology |
| The Cancer Drug Development Forum | |
| International Collaboration On Rare Diseases & Orphan Drugs |
- Stock Market
- Insiders
- Catarina Edfjäll
